Fever After Simultaneous Versus Sequential Vaccination in Young Children

Fever Clinical Trial

Official title:

A Prospective, Randomized, Open-label Clinical Trial to Assess Fever Following Simultaneous Versus Sequential Administration of PCV13, DTaP Vaccine and IIV in Young Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03165981
• Other study ID #: Pro00082484
• Secondary ID: 200 2012 53663 0
• Status: Completed
• Phase: Phase 4
• Start date: August 25, 2017
• Est. completion date: January 15, 2018

Study information

• Verified date: February 2019
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, randomized open-label clinical trial that will be conducted during the 2017-2018 influenza season. During the 2017-2018 season, approximately 280 children will be enrolled at Duke University Medical Center and Kaiser Permanente Northern California. Eligible children will be randomized to receive simultaneous or sequentially administered US licensed PCV13, US-licensed DTaP vaccine, and US-licensed inactivated influenza vaccine (IIV). Children in the simultaneous group will receive PCV13, DTaP, and IIV vaccines at Visit 1, and then return for a health education visit without vaccination about 2 weeks later (Visit 2). Children in the sequential group will receive both PCV13 and DTaP without IIV at Visit 1, and then will receive IIV and health education about 2 weeks later (Visit 2). Parents will record the occurrence of fever, solicited adverse events, medical care utilization, and receipt of antipyretics over 8 days following Visit 1 and Visit 2. In addition, febrile seizures and serious adverse events will be recorded for the entire study period (from enrollment through 8 days following the Visit 2) as determined through parental report and chart review. Parental perceptions about their child's vaccine schedule will be assessed on the 8th day following Visit 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 221
• Est. completion date: January 15, 2018
• Est. primary completion date: January 15, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Months to 16 Months

Eligibility

Inclusion Criteria:

1. 12 through 16 months of age (i.e. from the 1-year birthday until the day before 17 months of age) at the time of vaccination

2. Stable health as determined by investigator's clinical examination and assessment of child's medical history

3. Has received all immunizations recommended by Advisory Committee for Immunization Practices (ACIP) during the first year of life with the exception of rotavirus and influenza vaccines.

4. The parent(s)/ legally authorized representative(s) LAR(s) intend for the child to receive DTaP and PCV13 in addition to this season's IIV

5. The parent(s)/LAR(s) must be willing and capable of providing permission for their child to participate through the written informed consent process

6. The parent(s)/LAR(s) must be able to comply with the requirements of the protocol (e.g., completion of the memory aid (either electronic or paper diary), return for follow-up visits, respects intervals between the visits and have telephone access.

7. The parent(s)/LAR(s) must be English speaking

8. The parent(s)/LAR(s) must agree to sign a medical release for the child so that study personnel may obtain medical information about the child's health (if needed)

Exclusion Criteria:

1. History of any seizure (including febrile seizure) in the child or a febrile seizure in a first degree relative

2. Has already completed influenza vaccination during the current season per ACIP recommendations

3. Receipt of more than 3 previous doses of DTaP

4. Received the 3rd dose of DTaP within 6 months of Visit 1

5. Receipt of more than 3 previous doses of PCV13

6. Received the 3rd dose of PCV13 within 8 weeks of Visit 1

7. History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any influenza, diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or pneumococcal vaccine.

8. History of a severe allergic reaction (e.g., anaphylaxis) to any component (including egg protein) of any of the three vaccines used in this study; or a latex allergy.

9. History of Guillain-Barré syndrome within 6 weeks following a prior dose of influenza, DTaP, or tetanus toxoid containing vaccine

10. History of a progressive neurologic disorder

11. History of encephalopathy within 7 days of a previous pertussis-containing vaccine

12. History of collapse within 3 days after a prior dose of DTaP

13. Received any other licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Visit 1

14. Received an experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 28 days prior to Visit 1, or expects to receive an experimental/investigational agent during the study period (up to 8 days after visit 2)

15. A moderate to severe acute illness within 72 hours of Visit 1

16. A reported temperature greater than or equal to 100.4°F (38.0°C) within 72 hours prior enrollment or a temperature (measured by temporal artery thermometer) greater than or equal to 100.4°F (38.0°C) at the time of enrollment

17. Receipt of an antipyretic medication (acetaminophen or ibuprofen) within 24 hours prior to enrollment

18. Parent(s)/LAR is planning to administer a prophylactic antipyretic or medication on the day of, and/or within 7 days following Visit 1 or Visit 2

19. Long term (at least 14 consecutive days) oral corticosteroids (prednisone 2 mg/kg/day or equivalent other glucocorticoid), any parenteral steroids, high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) or other immune-modifying drugs or immunosuppressants within the preceding 6 months prior to Visit 1

20. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and or their provider's routine physical examination

21. Has an active neoplastic disease, a history of any hematologic malignancy, current bleeding disorder, or taking anticoagulants.

22. Unable to receive an intramuscular injection in the thigh

23. Any condition deemed by the investigator to place the child at increased risk as a result of their participation in the study

24. Any child or grandchild of a study investigator or study team member

Related Conditions & MeSH terms

• Febrile Seizure
• Fever
• Fever After Vaccination
• Seizures
• Seizures, Febrile

Intervention

Biological:
• PCV13
ACIP Recommended vaccine
• DTaP
ACIP Recommended vaccine
• IIV
ACIP Recommended vaccine

Locations

Country	Name	City	State
United States	Centers for Disease Control and Prevention	Atlanta	Georgia
United States	Duke University	Durham	North Carolina
United States	Kaiser Permanente Northern California	Oakland	California

Sponsors (3)

Lead Sponsor	Collaborator
Duke University	Centers for Disease Control and Prevention, Kaiser Permanente

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Fever Following Vaccination	Proportion of children with fever (temperature = 38.0°C or = 100.4°F) on day 1 and/or day 2 following Visit 1 and/or Visit 2.	2 days post administration
Secondary	Number of Participants With Fever Visit 1	Proportion of children with fever (temperature = 38.0°C or = 100.4°F) on day 1 and/or day 2 following Visit 1	2 days post administration
Secondary	Number of Participants With Fever Visit 2	Proportion of children with fever (temperature = 38.0°C or = 100.4°F) on day 1 and/or day 2 following Visit 2	2 days post administration
Secondary	Number of Participants With Grade 2 and/or 3 Following Visit 1	Proportions of children with moderate/severe fever (Grade 2 and/or 3) on day 1 and/or day 2 following Visit 1. (Moderate/severe fever: = 38.6°C or = 101.4°F)	2 days post administration
Secondary	Number of Participants With Grade 2 and/or 3 Following Visit 2	Proportions of children with moderate/severe fever (Grade 2 and/or 3) on day 1 and/or day 2 following Visit 2.	2 days post administration
Secondary	Number of Participants With Grade 2 and/or 3 Following Visit 1 and Visit 2	Proportions of children with moderate/severe fever (Grade 2 and/or 3) on day 1 and/or day 2 following Visit 1 and Visit 2 combined.	2 days post administration
Secondary	Duration of Fever - Visit 1	Average number of consecutive days of fever (temperature = 38.0°C or = 100.4°F) per subject for fever starting on day 1 or 2 following Visit 1. Note: fever starting on day 1 or 2 could continue through day 8.	8 days post administration
Secondary	Duration of Fever - Visit 2	Average number of consecutive days of fever (temperature = 38.0°C or = 100.4°F) per subject for fever starting on day 1 or 2 following Visit 2. Note: fever starting on day 1 or 2 could continue through day 8.	8 days post administration
Secondary	Duration of Fever - Visit 1 and 2 Combined	Average number of consecutive days of fever (temperature = 38.0°C or = 100.4°F) per subject for fever starting on day 1 or 2 following and Visit 1 and Visit 2 combined. Note: fever starting on day 1 or 2 could continue through day 8.	8 days post administration
Secondary	Number of Participants With Medical Care Utilization - Visit 1	Proportion of children with medical care utilization (telephone call, medical office visit, emergency department visit, or hospital admission) for fever on day 1 and/or day 2 following Visit 1.	2 days post administration
Secondary	Number of Participants With Medical Care Utilization - Visit 2	Proportion of children with medical care utilization (telephone call, medical office visit, emergency department visit, or hospital admission) for fever on day 1 and/or day 2 following Visit 2.	2 days post administration
Secondary	Number of Participants With Medical Care Utilization - Visit 1 and 2 Combined	Proportion of children with medical care utilization (telephone call, medical office visit, emergency department visit, or hospital admission) for fever on day 1 and/or day 2 following Visit 1 and Visit 2 combined.	2 days post administration